USRE38934E1 - Method and reagents for N-alkylating ureides - Google Patents

Method and reagents for N-alkylating ureides Download PDF

Info

Publication number
USRE38934E1
USRE38934E1 US10/375,340 US37534003A USRE38934E US RE38934 E1 USRE38934 E1 US RE38934E1 US 37534003 A US37534003 A US 37534003A US RE38934 E USRE38934 E US RE38934E
Authority
US
United States
Prior art keywords
methoxymethyl
ureide
acid
phenyl
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/375,340
Inventor
Daniela Gutman
Hershel Herzog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Priority to US10/375,340 priority Critical patent/USRE38934E1/en
Application granted granted Critical
Publication of USRE38934E1 publication Critical patent/USRE38934E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms

Definitions

  • the invention relates to a new means for N-alkylating ureides that is higher yielding, more convenient, and safer to use than techniques practiced heretofore.
  • This approach is particularly suited to preparing N-(alkoxyalkylene) ureides, which include anti-convulsant drugs of the N-substituted barbituric acid class.
  • Ureides are a class of imides of general structure I: Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
  • hypnotics such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea
  • anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
  • U.S. Pat. No. 4,628,056 teaches a method of making 1,3 bis(methoxymethyl)-5,5-diphenyl barbituric acid (also called (N,N′-bis(methoxymethyl)-5,5-diphenyl barbituric acid) by dissolving diphenyl barbituric acid in cooled dimethylformamide, adding sodium hydride, then adding chloromethyl methyl ether.
  • Chloromethyl methyl ether has been widely used to alkylate with a methoxymethylene function. However, it is highly toxic and regulated as a carcinogen. It is extremely volatile and flammable under exothermic reaction conditions, and alternatives to its use are strongly desirable.
  • the invention method avoids the use of volatile, carcinogenic chloromethyl methyl ether, replacing that reagent with a more reactive, less volatile alternative which may be generated in situ (without risk to the operator).
  • the invention solves a previously unrecognized problem limiting the applicability of methoxymethanesulfante alkylation to alcohols and amines. Ureides are much less basic than amines, so a different method for oxyalkylation is required.
  • This invention differs from the method of Karger et al. by using a ureide, a non-aqueous basic catalyst, and an aprotic solvent, modifications which were not previously known or suggested.
  • the inventive method allows use of a variety of sulfonates to prepare a broad variety of oxyalkylated ureides, some not previously known. The simplicity and convenience of the invention provide advantages that were not previously appreciated.
  • a method of N-alkoxyalkylating ureides comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium.
  • the alkylating agent III may be combined directly with the ureide, or the method may include reacting in situ a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the alkylating agent III.
  • the method preferably involves isolating the resultant N-alkoxyalkylated ureide.
  • the ureide is a 5,5-disubstituted barbituric acid, phenytoin, glutethimide, or ethosuximide.
  • the alkylating agent may be methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, or methoxymethyl p-toluenesulfonate.
  • the base may be selected from sodium hydride, triethyl amine, and di-isopropyl ethyl amine.
  • the process includes the step of reacting a dialkoxymethane and a mixed acetic sulfonic anhyride to produce the resulting ester of the sulfonic acid, that reaction may be carried out in the same vessel as the following reaction with the ureide (done sequentially).
  • a preferred process comprises N-alkylating 5,5-diphenyl-barbituric acid with a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid.
  • a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate
  • the invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide, methods of making them, and a method comprising administering to a patient an effective amount of a pharmaceutical agent selected from the group consisting of N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide.
  • the reagent class which possesses the desirable N-alkylating properties is characterized as compounds of structure III where the R groups are preferably as follows:
  • R 3 R 4 R 5 1. methoxymethyl methanesulfonate H H CH 3 2. ethoxymethyl methanesulfonate CH 3 H CH 3 3. benzyloxymethyl methanesulfonate phenyl H CH 3 4. methoxymethyl ethanesulfonate H H C 2 H 3 5. methoxymethyl benzenesulfonate H H phenyl 6. methoxymethyl ⁇ -toluenesulfonate H H tolyl 7. methoxybenzylidene methanesulfonate H phenyl CH 3 8. methoxyethylidene methanesulfonate H CH 3 CH 3 A particularly preferred reagent is methoxymethyl methanesulfonate.
  • the ureides which have been shown to be alkylated belong to the family of compounds having structure I: which may be linear (with R 1 and R 2 being alkyl, aryl, or arylakyl), or cyclic (R 1 and R 2 bonded to form a ring).
  • Tables 2 and 3 depict ureide drugs.
  • the preferred family of reactant ureides is the barbituric acids dissolving at 5, as in structure IV with the R groups preferably being the same or different alkyl or aryl groups, and most preferably with both R groups being phenyl.
  • Analogous products resulting from the process of the invention, where 5,5-diphenyl-barbituric acid is a substrate include:
  • the N-methoxymethyl derivative of 5,5-diphenylbarbituric acid may be prepared by the process of this invention.
  • the substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1.
  • a very strong base as strong as a hydride, e.g. NaH
  • reagent 1 of Table 1 one equivalent is added of the alkoxy-alkylating agent
  • N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide.
  • the monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
  • stoichiometric amounts of the components are used. That is, for mono-alkylation, the ratio of ureide:alkylating agent:base is about 1:1:2; for di-substitution, the ratio is about 1:2:2, and so on. Different ratios may be appropriate depending on the reaction conditions. A person of ordinary skill will recognize that by varying these ratios, the reaction may proceed faster or slower and have higher or lower yield of end products. For example, as discussed above, mono-substitution of a ureide of the barbituric acid family is favored by using excess base.
  • the base may be as strong as sodium hydride or as weak as a tertiary amine.
  • the basic catalyst is preferably an amine that does not compete with the substrate ureide (or imide). To this end primary and secondary amine catalysts are excluded. Tertiary amines, which react more slowly with the alkylating species, are preferred to minimize the competing reaction through steric hindrance (branching in the amine substituents). Especially preferred for this attribute are highly hindered amines, such as the readily available amine, ethyl di-isopropyl amine.
  • the hindrance inhibits quarternization of the catalyst amine by the alkylating agent in competition with the ureide substrate, while not interfering significantly with ability of the amine to act as a base (accept a proton).
  • Useful bases include sodium hydride, potassium hydride, lithium hydride, triethylamine, tri-n-propylamine, and di-isopropyl ethyl amine.
  • the solvent is chosen so as not to compete with the substrate and to maximize the rate of alkylation.
  • dipolar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, N-methylpyrrolidione, etc., appears to optimize these attributes. Otherwise, any dipolar aprotic solvent may be selected by the person of ordinary skill so long as the solvent is capable of bringing the reactants into solution.
  • the preferred temperature range for the alkylation process is at or near ambient temperature (25 ⁇ 5° C.). Higher temperatures tend to stimulate competitive side-reactions between the alkylating agent and the tertiary amine catalyst (where the latter is being used).
  • Yields according to the invention are at least as high as with prior art methods.
  • the high yields complement the other advantages of the inventive method including the facts that it is much safer, more convenient, and economical, and allows for ready synthesis of new compounds.
  • a preferred embodiment of the inventive alkylation process (which employs the preferred substrate and preferred reagent illustrated above) affords the N,N′ disubstituted barbituric acid depicted as structure V where the R groups are phenyl.
  • the alkylation preferably takes place in a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide.
  • a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide.
  • aprotic solvents may also be employed, so long as they are compatible with the base.
  • This alkylating technique is particularly novel and convenient in that the active alkylating species may also be generated in situ by employing precursor substances without isolation of the sulfonate reagent itself.
  • Dimethoxymethane (10.85 g) was added at 0° C. to 19.7 g of acetylmethanesulfonate. The reaction was stirred at 25° C. for 2 hours. The resultant solution was then added gradually over 45 minutes to a mixture of 10 g of 5,5-diphenylbarbituric acid and 13.85 g of N,N-diisopropyl ethyl amine in 60 ml of dry dimethylformamide. The resultant reaction mixture was stirred for about 15 minutes and then diluted with 180 ml of 2 N HCl, followed by 300 ml of ethyl acetate.
  • Completion of the reaction may be checked using conventional methods such as by TLC on silica (mobile phase chloroform methanol 98:2).
  • the reaction mixture is diluted with 360 ml of water and extracted with 480 ml of ethyl acetate.
  • the organic layer is separated and washed twice with 150 ml of water.
  • the solvent is removed by distillation under reduced pressure in order to obtain crude product.
  • the crude product may be purified by crystallization from 4 parts of toluene.
  • the mixture is heated to reflux to dissolve and cooled to room temperature. According to HPLC the product of the inventive method has 98-100% purity, and yields of about 60-80% may be expected.
  • the monosubstituted methoxymethyl derivative is obtained by optimizing the procedure of Example 1A to favor monosubstitution, using an excess of NaH and one equivalent of alkylating agent per equivalent of ureide.
  • the monosubstituted product is separated and characterized.
  • the compounds of examples 2-6 have advantageous pharmaceutical properties over a sustained period of time. They may be used to treat mammals including humans for convulsions, seizures, muscle stiffness, nervous strain or anxiety, by administering an effective amount of the compound in a pharmaceutically acceptable carrier to the patient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I
Figure USRE038934-20060110-C00001
with an alkylating agent of structure III
Figure USRE038934-20060110-C00002
in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.

Description

BACKGROUND OF THE INVENTION
The invention relates to a new means for N-alkylating ureides that is higher yielding, more convenient, and safer to use than techniques practiced heretofore. This approach is particularly suited to preparing N-(alkoxyalkylene) ureides, which include anti-convulsant drugs of the N-substituted barbituric acid class.
The term ureide is used in e.g. Foye, Principles of Medicinal Chemistry, 3d ed. (1990), pp. 164, 179, which is incorporated herein by reference. Ureides are a class of imides of general structure I:
Figure USRE038934-20060110-C00003
Examples, include hypnotics, such as acecarbromal, apronalide, bromisolvalum, capuride, carbromal, and ectylurea; and anticonvulsant drugs such as hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates such as barbituric acid (structure II).
Figure USRE038934-20060110-C00004
U.S. Pat. No. 4,628,056 teaches a method of making 1,3 bis(methoxymethyl)-5,5-diphenyl barbituric acid (also called (N,N′-bis(methoxymethyl)-5,5-diphenyl barbituric acid) by dissolving diphenyl barbituric acid in cooled dimethylformamide, adding sodium hydride, then adding chloromethyl methyl ether. Chloromethyl methyl ether has been widely used to alkylate with a methoxymethylene function. However, it is highly toxic and regulated as a carcinogen. It is extremely volatile and flammable under exothermic reaction conditions, and alternatives to its use are strongly desirable.
Almost three decades ago, methoxymethyl methanesulfonate was identified as an agent for alkylating some alcohols and amines in a self-catalyzing reaction. Karger et al., J.A.C.S. 91:5663 (1969). With amines, the reaction was complex and led to salts, dimers, and other side products being formed. This method has not been applied to alkylation of ureides, or imides, for which there are major differences in electron availability at nitrogen.
SUMMARY OF THE INVENTION
The invention method avoids the use of volatile, carcinogenic chloromethyl methyl ether, replacing that reagent with a more reactive, less volatile alternative which may be generated in situ (without risk to the operator).
The invention solves a previously unrecognized problem limiting the applicability of methoxymethanesulfante alkylation to alcohols and amines. Ureides are much less basic than amines, so a different method for oxyalkylation is required. This invention differs from the method of Karger et al. by using a ureide, a non-aqueous basic catalyst, and an aprotic solvent, modifications which were not previously known or suggested. The inventive method allows use of a variety of sulfonates to prepare a broad variety of oxyalkylated ureides, some not previously known. The simplicity and convenience of the invention provide advantages that were not previously appreciated.
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium. The alkylating agent III may be combined directly with the ureide, or the method may include reacting in situ a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the alkylating agent III. The method preferably involves isolating the resultant N-alkoxyalkylated ureide.
Preferably, the ureide is a 5,5-disubstituted barbituric acid, phenytoin, glutethimide, or ethosuximide. The alkylating agent may be methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, or methoxymethyl p-toluenesulfonate. The base may be selected from sodium hydride, triethyl amine, and di-isopropyl ethyl amine.
When the process includes the step of reacting a dialkoxymethane and a mixed acetic sulfonic anhyride to produce the resulting ester of the sulfonic acid, that reaction may be carried out in the same vessel as the following reaction with the ureide (done sequentially).
A preferred process comprises N-alkylating 5,5-diphenyl-barbituric acid with a reagent selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, in the presence of di-isopropyl ethyl amine and isolating the resultant N,N′-bismethoxymethyl-5,5-diphenyl-barbituric acid.
The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide, methods of making them, and a method comprising administering to a patient an effective amount of a pharmaceutical agent selected from the group consisting of N-methoxymethyl-5,5-diphenyl-barbituric acid, N-methoxymethyl ethosuximide and N-methoxymethyl glutethimide.
Further objectives and advantages will become apparent from a consideration of the description and examples.
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS In describing preferred embodiments of the present invention illustrated in the drawings, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents which operate in a similar manner to accomplish a similar purpose.
The reagent class which possesses the desirable N-alkylating properties is characterized as compounds of structure III
Figure USRE038934-20060110-C00005
where the R groups are preferably as follows:
    • R3=H, lower alkyl, phenyl, or substituted phenyl
    • R4=H, lower alkyl, phenyl, or substituted phenyl
    • R5=lower alkyl, phenyl, or substituted phenyl
      Particular examples of structures belonging to this class are listed in Table 1:
TABLE 1
Compound III R3 R4 R5
1. methoxymethyl methanesulfonate H H CH3
2. ethoxymethyl methanesulfonate CH3 H CH3
3. benzyloxymethyl methanesulfonate phenyl H CH3
4. methoxymethyl ethanesulfonate H H C2H3
5. methoxymethyl benzenesulfonate H H phenyl
6. methoxymethyl ρ-toluenesulfonate H H tolyl
7. methoxybenzylidene methanesulfonate H phenyl CH3
8. methoxyethylidene methanesulfonate H CH3 CH3

A particularly preferred reagent is methoxymethyl methanesulfonate.
The ureides which have been shown to be alkylated belong to the family of compounds having structure I:
Figure USRE038934-20060110-C00006
which may be linear (with R1 and R2 being alkyl, aryl, or arylakyl), or cyclic (R1 and R2 bonded to form a ring). Tables 2 and 3 (taken from Foye et al., Principles of Medicinal Chemistry, 3rd Edition (Lea and Febiger 1990), pp.164 and 179) depict ureide drugs.
TABLE 2
Structure of Anticonvulsant Drugs Containing the Ureide Structure
Figure USRE038934-20060110-C00007
Class of Compounds
Figure USRE038934-20060110-C00008
Barbiturates
Figure USRE038934-20060110-C00009
Hydantoias
Figure USRE038934-20060110-C00010
Glutarimides
Figure USRE038934-20060110-C00011
Oxazolidipediopes
Figure USRE038934-20060110-C00012
Succinimides
Figure USRE038934-20060110-C00013
TABLE 3
Ureide Hypnotics
Figure USRE038934-20060110-C00014
General Structure
Generic Name Chemical Name R1 R2
Acecarbromal (1-acetyl)-2-(2- bromo-2-ethylbutyryl) urea CH3CO
Figure USRE038934-20060110-C00015
Aprohalide (2-isopropyl-4- pentencyl)urea H
Figure USRE038934-20060110-C00016
Bromisovalum (2-bromo-3-methyl- butyryl)urea H
Figure USRE038934-20060110-C00017
Capuride (2-ethyl-3-methyl- valeryl)urea H
Figure USRE038934-20060110-C00018
Carbromal (2-bromo-2-ethyl- butyryl)urea H
Figure USRE038934-20060110-C00019
Ectylurea (2-ethyl-cis- crulonoyl)urea H
Figure USRE038934-20060110-C00020

Examples of these ureides include those listed above and:
  • glutethimide (3-ethyl-3-phenyl-piperidine-2,6-dione)
  • phenytoin (5,5-diphenyl-2,4-imidazolidinedione)
  • ethosuximide (3-ethyl-3-methyl-2,5-pyrrolidinedione)
  • 5,5-diphenylbarbituric acid
  • 5-phenyl-5-ethylbarbituric acid
  • 5,5-diethylbarbituric acid
The preferred family of reactant ureides is the barbituric acids dissolving at 5, as in structure IV with the R groups preferably being the same or different alkyl or aryl groups, and most preferably with both R groups being phenyl.
Figure USRE038934-20060110-C00021
Analogous products resulting from the process of the invention, where 5,5-diphenyl-barbituric acid is a substrate, include:
    • N,N′-bismethoxymethyl derivative using reagent 2 of Table 1.
    • N,N′-bismethoxybenzylidene derivative using reagent 7 of Table 1.
    • N,N′-bismethoxyethylidene derivative using reagent 8 of Table 1.
    • N,N′-bisbenzyloxymethyl derivative using reagent 3 of Table 1.
The N-methoxymethyl derivative of 5,5-diphenylbarbituric acid (Formula IX) may be prepared by the process of this invention.
Figure USRE038934-20060110-C00022
The substrate 5,5-diphenylbarbituric acid is converted to its di-anion salt with a very strong base (as strong as a hydride, e.g. NaH) and then one equivalent is added of the alkoxy-alkylating agent, reagent 1 of Table 1. N-methoxymethyl-5,5-diphenylbarbituric acid is obtained by optimizing the reaction to favor monosubstitution. For example, an excess of the very strong base NaH is used, greater than two molar equivalents per mole of the ureide. The monosubstituted product is separated by chromatography or other conventional methods and may be characterized by melting point and nuclear magnetic resonance.
Pharmaceutically-effective salts of the alkylated ureides are also contemplated within the scope of the invention.
In general, stoichiometric amounts of the components are used. That is, for mono-alkylation, the ratio of ureide:alkylating agent:base is about 1:1:2; for di-substitution, the ratio is about 1:2:2, and so on. Different ratios may be appropriate depending on the reaction conditions. A person of ordinary skill will recognize that by varying these ratios, the reaction may proceed faster or slower and have higher or lower yield of end products. For example, as discussed above, mono-substitution of a ureide of the barbituric acid family is favored by using excess base.
For the reaction to proceed a non-aqueous basic catalyst is required. The base may be as strong as sodium hydride or as weak as a tertiary amine. For disubstituted products, the basic catalyst is preferably an amine that does not compete with the substrate ureide (or imide). To this end primary and secondary amine catalysts are excluded. Tertiary amines, which react more slowly with the alkylating species, are preferred to minimize the competing reaction through steric hindrance (branching in the amine substituents). Especially preferred for this attribute are highly hindered amines, such as the readily available amine, ethyl di-isopropyl amine. The hindrance inhibits quarternization of the catalyst amine by the alkylating agent in competition with the ureide substrate, while not interfering significantly with ability of the amine to act as a base (accept a proton). Useful bases include sodium hydride, potassium hydride, lithium hydride, triethylamine, tri-n-propylamine, and di-isopropyl ethyl amine.
The solvent is chosen so as not to compete with the substrate and to maximize the rate of alkylation. The use of dipolar aprotic solvents such as dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, N-methylpyrrolidione, etc., appears to optimize these attributes. Otherwise, any dipolar aprotic solvent may be selected by the person of ordinary skill so long as the solvent is capable of bringing the reactants into solution. The preferred temperature range for the alkylation process is at or near ambient temperature (25±5° C.). Higher temperatures tend to stimulate competitive side-reactions between the alkylating agent and the tertiary amine catalyst (where the latter is being used).
Yields according to the invention are at least as high as with prior art methods. The high yields complement the other advantages of the inventive method including the facts that it is much safer, more convenient, and economical, and allows for ready synthesis of new compounds.
A preferred embodiment of the inventive alkylation process (which employs the preferred substrate and preferred reagent illustrated above) affords the N,N′ disubstituted barbituric acid depicted as structure V where the R groups are phenyl.
Figure USRE038934-20060110-C00023
N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid
The alkylation preferably takes place in a solvent which is usually a dipolar aprotic solvent like an N,N′-dialkylamide. However, other types of aprotic solvents may also be employed, so long as they are compatible with the base. This alkylating technique is particularly novel and convenient in that the active alkylating species may also be generated in situ by employing precursor substances without isolation of the sulfonate reagent itself. Thus, dimethoxymethane (structure VI) may be reacted with the mixed anhydride of acetic and methanesulfonic acids (structure VII) and the resulting in situ generated sulfonate ester, methoxymethyl methanesulfonate (structure VIII, which is structure III where R3=H, R4=H, and R5=CH3) may be applied without isolation or purification to the N-alkylation of the barbituric acid.
Figure USRE038934-20060110-C00024
The following examples are intended to illustrate various embodiments of the invention without limiting its scope.
EXAMPLE 1 N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid
A. Using a Hindered Tertiary Amine Catalyst
Dimethoxymethane (10.85 g) was added at 0° C. to 19.7 g of acetylmethanesulfonate. The reaction was stirred at 25° C. for 2 hours. The resultant solution was then added gradually over 45 minutes to a mixture of 10 g of 5,5-diphenylbarbituric acid and 13.85 g of N,N-diisopropyl ethyl amine in 60 ml of dry dimethylformamide. The resultant reaction mixture was stirred for about 15 minutes and then diluted with 180 ml of 2 N HCl, followed by 300 ml of ethyl acetate. The phases were separated and the ethyl acetate phase was washed first with 150 ml of saturated aqueous sodium chloride and then with 150 ml of 2N aqueous NaOH. The organic (ethyl acetate) phase was dried over anhydrous sodium sulfate, filtered and concentrated to dryness to give 12.2 g of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid. Crystalization from 48 ml of toluene afforded 10.5 g of pure product (79.6% yield).
B. Using Triethylamine as Catalyst
By the procedure of example A, using 10.84 g, of triethylamine (in place of 13.85 g of diisopropylethylamine), there resulted 10.62 g of crude alkylated product. Crystallization from 40 ml of toluene afforded 7.6 g (58.5%) of N,N′-bismethoxymethyl 5,5-diphenylbarbituric acid.
C. Using Sodium Hydride as Catalyst
By the procedure of example A, using 3.57 g of sodium hydride (60% dispersion in mineral oil) in place of the amine catalyst, there resulted after crystallization from toluene 5.0 g (38%) of N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
D. Using Acetylbenzenesulfonate in place of acetylmethanesulfonate
By the procedure of example A, using 28.55 g of acetylbenzenesulfonate in place of acetylmethanesulfonate (19.7 g), the pure alkylated product resulted in 75.5% yield.
Completion of the reaction may be checked using conventional methods such as by TLC on silica (mobile phase chloroform methanol 98:2). The reaction mixture is diluted with 360 ml of water and extracted with 480 ml of ethyl acetate. The organic layer is separated and washed twice with 150 ml of water. The solvent is removed by distillation under reduced pressure in order to obtain crude product. The crude product may be purified by crystallization from 4 parts of toluene. The mixture is heated to reflux to dissolve and cooled to room temperature. According to HPLC the product of the inventive method has 98-100% purity, and yields of about 60-80% may be expected.
EXAMPLE 2 N,N′-Bisethoxymethyl-5,5-diphenylbarbituric acid
By the procedure of Example 1A, using diethoxymethane (15.42 g) in place of dimethoxymethane (10.85 g), there is obtained a 68% yield of pure N,N′-bismethoxymethyl-5,5-diphenylbarbituric acid.
EXAMPLE 3 3-Methoxymethylphenytoin
By the procedure of 1A, using phenytoin (18 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 70% yield of 3-methoxymethylphenytoin.
EXAMPLE 4 N-Methoxymethylglutethimide
By the procedure of 1A, using glutethimide (15.5 g) in place of 5,5-diphenylbarbituric acid (10 g) there is obtained a 65% yield of N-methoxymethylglutethimide.
EXAMPLE 5 N-Methoxymethylethosuximide
By the procedure of 1A, using ethosuximide (10 g) in place of 5,5-diphenylbarbituric acid (10 g), there is obtained a 60% yield of N-methoxymethylethosuximide.
EXAMPLE 6 N-Methoxymethyl-5,5-diphenylbarbituric acid
The monosubstituted methoxymethyl derivative is obtained by optimizing the procedure of Example 1A to favor monosubstitution, using an excess of NaH and one equivalent of alkylating agent per equivalent of ureide. The monosubstituted product is separated and characterized.
The compounds of examples 2-6 have advantageous pharmaceutical properties over a sustained period of time. They may be used to treat mammals including humans for convulsions, seizures, muscle stiffness, nervous strain or anxiety, by administering an effective amount of the compound in a pharmaceutically acceptable carrier to the patient.
The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. Modifications and variations of the above-described embodiments of the invention are possible without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

Claims (32)

1. A method of N-alkylating ureides comprising reacting a ureide of formula I
Figure USRE038934-20060110-C00025
with an ester of a sulfonic acid of formula III
Figure USRE038934-20060110-C00026
in the presence of a base in an aprotic reaction medium, to provide a corresponding alkylated ureide, wherein R1 and R2 are each either non-cyclic alkyl, aryl, arylalkyl, or R1 and R2 together form a cyclic group having a total of at least 5 atoms each of which is selected from the group consisting of carbon, nitrogen and oxygen, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl.
2. A process of N-alkylation of a ureide comprising:
reacting a ureide of formula I
Figure USRE038934-20060110-C00027
with an ester of a sulfonic acid of Formula III
Figure USRE038934-20060110-C00028
in the presence of a base and an aprotic solvent, wherein one of R1 and R2 is NH2, NHCOCH3, or non-cyclic alkyl, aryl, arylalkyl, or haloalkyl, and the other of R1 and R2 is non-cyclic alkyl, aryl, arylalkyl, or haloalkyl, or wherein R1 and R2 together form a cyclic group selected from the group consisting of NHCOC(R6)(R7), NHC(R6)(R7), CH2CH2C(R6) (R7), OC(R6)(R7) and CH2C(R6)(R7), wherein R6 and R7, are each either noncyclic alkyl, aryl or arylalkyl, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl, to provide a resultant N-alkoxyalkylated ureide.
3. A process according to claim 2, wherein the ureide is a 5,5-disubstituted barbituric acid.
4. A process according to claim 2, wherein the ureide is 5,5-diphenyl barbituric acid, the ester of a sulfonic acid is selected from the group consisting of methoxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, and methoxymethyl p-toluenesulfonate, the base is di-isopropyl ethyl amine, and the resultant ureide is N,N′-bismethoxymethyl-5,5-diphenyl barbituric acid.
5. A process according to claim 2, wherein the ureide is selected from the group consisting of 5,5-diphenyl barbituric acid, phenytoin, glutethimide, ethosuximide, 5-phenyl-5-ethylbarbituric acid, and 5,5-diethylbarbituric acid.
6. A process according to claim 2, wherein the ureide is selected from the group consisting of acecarbromal, apronalide, bromisolvalum, capuride, carbromal, ectylurea, hydantoins, glutarimides, oxazolidinediones, succinimides, and barbiturates.
7. A process according to claim 2, wherein the ester of a sulfonic acid is methoxymethyl methanesulfonate.
8. A process according to claim 2, wherein the ester of a sulfonic acid is selected from the group consisting of ethoxymethyl methanesulfonate, benzyloxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, methoxymethyl p-toluenesulfonate, methoxylbenzylidene methanesulfonate, and methoxyethylidene methanesulfonate.
9. A process according to claim 2, wherein the base is non-aqueous with a strength between sodium hydride and a tertiary amine.
10. A process according to claim 2, wherein the base is a tertiary amine.
11. A process according to claim 2, wherein the base is selected from the group consisting of sodium hydride, potassium hydride, lithium hydride, triethyl amine tri-n-propylamine, and di-isopropy ethyl amine.
12. A process according to claim 2, wherein the ester of a sulfonic acid is produced in situ and is combined directly with the ureide without isolating the ester of a sulfonic acid.
13. A process according to claim 2, further comprising reacting a mixed anhydride of acetic acid and a sulfonic acid with a dialkoxymethane to provide the ester of the sulfonic acid in situ and combined with the ureide without isolating the ester of the sulfonic acid.
14. A process according to claim 2, wherein the ureide is 5,5-disubstituted barbituric acid, which is converted to its di-anion salt with a strong base, and one equivalent of the ester of a sulfonic acid is added, to provide the corresponding mono-alkylated barbituric acid.
15. A process according to claim 2, wherein the aprotic reaction medium is a dipolar solvent.
16. A process according to claim 2, wherein the dipolar solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, dimethylacetamide, sulfolane, and N-methylpyrrolidione.
17. A process according to claim 3, wherein the the ureide is 5,5-diphenyl barbituric acid, the ester of a sulfonic acid is selected from the group consisting of methoxymethyl methanesulfonate, ethoxymethyl methanesulfonate, benzyloxymethyl methanesulfonate, methoxymethyl ethanesulfonate, methoxymethyl benzenesulfonate, methoxymethyl p-toluenesulfonate, methoxylbenzylidene methanesulfonate, and methoxyethylidene methanesulfonate, the base is a non-aqueous base selected from a hydride or an amine, and the process further comprises isolating the resultant alkoxyalkylated 5,5-diphenyl-barbituric acid.
18. A process according to claim 17, wherein the ureide is alkoxyalkylated to an N-mono-alkoxyalkylated 5,5-diphenyl barbituric acid.
19. A process according to claim 18, wherein the ester is a methoxymethyl ester, the base is very strong and is present in excess, and the isolated compound is N-methoxymethyl-5,5-diphenylbarbituric acid.
20. An alkoxyalkylated ureide compound selected from the group consisting of N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and N-methoxymethyl-5,5-diphenylbarbituric acid .
21. A compound according to claim 20, wherein the compound is N-methoxymethyl ethosuximide.
22. A compound according to claim 20, wherein the compound is N-methoxymethyl glutethimide.
23. A compound according to claim 20, wherein the compound is N-methoxymethyl-5,5-diphenylbarbituric acid.
24. A method of treating a mammal for a condition selected from the group consisting of convulsions, seizures, muscle stiffness, or anxiety comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical agent comprising a compound according to claim 20.
25. A method of N-alkylating ureides comprising reacting a ureide of formula I
Figure USRE038934-20060110-C00029
with an ester of a sulfonic acid of formula III
Figure USRE038934-20060110-C00030
in the presence of a base in an aprotic reaction medium, to provide a corresponding alkylated ureide, wherein R1 and R2 together form a cyclic group having a total of at least 5 atoms each of which is selected from the group consisting of carbon nitrogen and oxygen, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl, or alkyl substituted phenyl, and R5=lower alkyl, phenyl, or alkyl substituted phenyl.
26. A process for N-alkoxyalkylation of a ureide comprising:
reacting a ureide of formula IV
Figure USRE038934-20060110-C00031
with an ester of a sulfonic acid of Formula III
Figure USRE038934-20060110-C00032
in the presence of a base and an aprotic solvent,
wherein X is O, NH, CH2, CH2—CH2 or C(O)NH, and wherein R6 and R7 are each either noncyclic alkyl, aryl or arylalkyl, and wherein R3=H, lower alkyl, phenyl, or alkyl substituted phenyl, R4=H, lower alkyl, phenyl or alkyl substituted phenyl, and R5=lower alky alkyl, phenyl, or alkyl substituted phenyl, to provide a resultant N-alkoxyalkylated ureide.
27. Isolated N-methoxymethyl- 5,5 -diphenylbarbituric acid.
28. A method of treating a mammal in need of treatment for a condition selected from the group consisting of convulsions, seizures, muscle stiffness, and anxiety, comprising administering to the mammal an effective amount of a pharmaceutical agent comprising N-methoxymethyl- 5,5 -diphenylbarbituric acid.
29. The method of claim 28, wherein the condition is convulsions.
30. The method of claim 28, wherein the condition is seizures.
31. The method of claim 28, wherein the condition is muscle stiffness.
32. The method of claim 28, wherein the condition is anxiety.
US10/375,340 1997-10-02 2003-02-27 Method and reagents for N-alkylating ureides Expired - Lifetime USRE38934E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/375,340 USRE38934E1 (en) 1997-10-02 2003-02-27 Method and reagents for N-alkylating ureides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/942,636 US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides
US10/375,340 USRE38934E1 (en) 1997-10-02 2003-02-27 Method and reagents for N-alkylating ureides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/942,636 Reissue US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides

Publications (1)

Publication Number Publication Date
USRE38934E1 true USRE38934E1 (en) 2006-01-10

Family

ID=25478386

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/942,636 Ceased US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides
US10/073,051 Expired - Fee Related US6664262B2 (en) 1997-10-02 2002-02-12 N-methoxymethyl-5,5-diphenylbarbituric acid
US10/375,340 Expired - Lifetime USRE38934E1 (en) 1997-10-02 2003-02-27 Method and reagents for N-alkylating ureides
US10/687,712 Expired - Fee Related US6906079B2 (en) 1997-10-02 2003-10-17 Method and reagents for N-alkylating ureides

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/942,636 Ceased US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides
US10/073,051 Expired - Fee Related US6664262B2 (en) 1997-10-02 2002-02-12 N-methoxymethyl-5,5-diphenylbarbituric acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/687,712 Expired - Fee Related US6906079B2 (en) 1997-10-02 2003-10-17 Method and reagents for N-alkylating ureides

Country Status (13)

Country Link
US (4) US6093820A (en)
EP (2) EP1342718B1 (en)
JP (2) JP4061018B2 (en)
CN (2) CN1193019C (en)
AT (2) ATE257153T1 (en)
AU (1) AU758506B2 (en)
CA (1) CA2304970C (en)
DE (2) DE69820895T2 (en)
DK (2) DK1027339T3 (en)
ES (2) ES2214736T3 (en)
IL (2) IL135284A (en)
PT (2) PT1342718E (en)
WO (1) WO1999018084A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029902A1 (en) * 2002-02-01 2004-02-12 Rajinder Singh 2,4-Pyrimidinediamine compounds and their uses
US20040224947A1 (en) * 2000-07-26 2004-11-11 Moros Daniel A. Non-sedating barbiturate compounds as neuroprotective agents
US20050234049A1 (en) * 2003-07-30 2005-10-20 Rajinder Singh Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US20060035915A1 (en) * 2000-07-26 2006-02-16 Taro Pharmaceutical Industries, Ltd. Non-sedating barbituric acid derivatives
US20060122208A1 (en) * 2000-07-26 2006-06-08 Daniella Gutman Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US20060234983A1 (en) * 2005-01-19 2006-10-19 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070072886A1 (en) * 2002-12-11 2007-03-29 Daniel Moros Method of treating movement disorders using barbituric acid derivatives
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
WO2012058216A2 (en) 2010-10-27 2012-05-03 The Gillette Company Composition dispensing device comprising a non-foaming hydrating composition
WO2013025772A2 (en) 2011-08-16 2013-02-21 The Gillette Company Composition dispensing device comprising a moisturizing composition
WO2015066486A1 (en) 2013-11-01 2015-05-07 The Gillette Company Shave care composition for a liquid dispensing razor

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CN1896084A (en) * 2002-01-30 2007-01-17 塔罗制药工业有限公司 Non-sedating barbituric acid derivatives
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
US8853257B2 (en) 2005-11-21 2014-10-07 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
WO2007057889A2 (en) * 2005-11-21 2007-05-24 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
US20120278179A1 (en) 2011-04-28 2012-11-01 Ray Campbell Systems and methods for deducing user information from input device behavior

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE2622981A1 (en) 1976-05-21 1977-12-08 Unisearch Ltd (N)-Haloalkyl nitrogen-contg. heterocyclics prodn. - by reacting (N)-heterocyclics e.g. barbiturates with bis-haloalkyl sulphates, e.g. bis-chloroethyl sulphate
US4628056A (en) * 1983-09-14 1986-12-09 Taro Pharmaceutical Industries Ltd. Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents
DE4028040A1 (en) 1990-09-05 1992-03-12 Chemie Linz Deutschland N-Alkylation of urea cpds. - by reacting urea cpd. with alkylating agent in diluent in presence of phase transfer catalyst and solid base
US6184238B1 (en) 1996-12-26 2001-02-06 Nikken Chemicals Co., Ltd. N-hydroxyurea derivative and pharmaceutical composition containing the same
EP1083172A1 (en) 1998-05-26 2001-03-14 Rimma Iliinichna Ashkinazi N-substituted derivatives of 5-oxyiminobarbituric acid
WO2001079185A1 (en) 2000-04-18 2001-10-25 Kenneth Curry Novel amino carboxy alkyl derivatives of barbituric acid
WO2002007729A1 (en) 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
US6664262B2 (en) 1997-10-02 2003-12-16 Taro Pharmaceuticals Industries Ltd. N-methoxymethyl-5,5-diphenylbarbituric acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204518A1 (en) * 1973-02-28 1976-02-12 Kendall & Co PROCEDURE TO PREPARE N-MONO (ALCOXIMETHYL) PHENOBARBITAL
DE19504623A1 (en) 1995-02-13 1996-08-14 Bayer Ag Process for the preparation of N-substituted cyclic imides

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE2622981A1 (en) 1976-05-21 1977-12-08 Unisearch Ltd (N)-Haloalkyl nitrogen-contg. heterocyclics prodn. - by reacting (N)-heterocyclics e.g. barbiturates with bis-haloalkyl sulphates, e.g. bis-chloroethyl sulphate
US4628056A (en) * 1983-09-14 1986-12-09 Taro Pharmaceutical Industries Ltd. Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents
DE4028040A1 (en) 1990-09-05 1992-03-12 Chemie Linz Deutschland N-Alkylation of urea cpds. - by reacting urea cpd. with alkylating agent in diluent in presence of phase transfer catalyst and solid base
US6184238B1 (en) 1996-12-26 2001-02-06 Nikken Chemicals Co., Ltd. N-hydroxyurea derivative and pharmaceutical composition containing the same
US6664262B2 (en) 1997-10-02 2003-12-16 Taro Pharmaceuticals Industries Ltd. N-methoxymethyl-5,5-diphenylbarbituric acid
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
EP1083172A1 (en) 1998-05-26 2001-03-14 Rimma Iliinichna Ashkinazi N-substituted derivatives of 5-oxyiminobarbituric acid
WO2001079185A1 (en) 2000-04-18 2001-10-25 Kenneth Curry Novel amino carboxy alkyl derivatives of barbituric acid
WO2002007729A1 (en) 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
Aldrich Chemical Catalog, 1990-1991, p. 303. *
Bhardwaj et al.: "Pentobarbital Inhibits extracellular release of dopamine in the Ischemic Striatum"; Journal of Neural Transmission [GenSect] (1990) 82; pp. 111-117.
Casara et al.: "Synthesis of Acid Stable Fluorinated Acyclonucleosides as Potential Antiviral Agents"; Tetrahedron Letters, vol. 32, No. 31, pp. 3823-3826, 1991.
Foye, "Principles of Medicinal Chemistry", 3rd ed., 1990, pp. 164, 179. *
Groth et al., EP-726252, (1996) (Abstract only). *
JP Gesson, JC Jacquesy, D. Rambaud, A practical method for N-alkylation of succinimide and glutarimide, Bulletin De La Societe Chimique De France, vol. 129, No. 3, 1992, pp. 227-231. *
Karger et al., "Methoxymethyl Methanesulfonate, N Novel Active Oxyakylating Agent", Journal of the American Chemical Society, 91:5663 (1969). *
Loudon et al: "Organic Chemistry"; Addison-Wesley (1984), pp. 617, 721-722, 1061-1064, 1086-1088, 1194.
Masuda et al.: "Relationships Between Plasma Concentrations of Diphenythydantoin, Phenobarbital, Carbamazepine, and 3-Sulfamoylmethyl-1,2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals"; Epilepsia, vol. 20, December 1979, pp. 623-633.
McElvain: "5,5-Diphenylbarbituric Acid"; vol. 57, pp. 1303-1304, (1935).
P. Casara et al., Synthesis of acid stable fluorinated acylnacleosides, vol. 32, No. 31, 1991, pp. 3823-3826. *
Raines, et al., "A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse," Journal of Pharmacology and Experimental Therapeutics, 186:315-322 (1973).
Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog," The FASEB J., 13(4):A475,Ansract 394.2 (1999).
Raines, et al., "Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Rat," The FASEB J., 10:A-155, Abstract 895 (1996).
Raines, et al., "Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse," Epilepsia, 20:105-113 (1979).
Raines, et al., "The Effects of 5,5-Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity," Epilepsia,16:575-581 (1975).
Raines, et al.,"Serum and Brain Levels of 5-5-Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) in the Rat," Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996).
Samour et al. DE1939787, (1970) (Abstract only). *
Samour et al.: "Anticonvulsants. 1, Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin"; Journal of Medicinal Chemistry, 1971, vol. 14, No. 3 pp. 187-189.
Sircar, "CLXXIII.-The Influence of Groups and Associated Rings on the Stability of Certain Heterocyclic Systems. Part II. The Substituted Succinimides"; Journal of the Chemical Society, May 1927, pp. 1252-1258.
Susumu Kamata, Nobuhiro Haga, Takeaki Matsui and Wataru Nagata, Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Systhesis of N-Phthalidyl 5-Fluorouracil Derivatives, Chemical And Pharmaceutical Bulletin, vol. 33, No. 8, 1985, pp. 3160-3175. *
Tagmann et al; Helv. Chim. Acta 35, 1541-1549 (1952).
Thacker et al., "A Method for Determination of 5,5-Diphenylbarbituric Acid and Separation from 1,3-Dimethoxymethyl-5,5-Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography," Journal of Chromatography B, 710:149-155 (1998).
The Merck Index; An Encyclopedia of Chemicals, Drugs, and Biologicals; Tenth Edition, Published by Merck & Co., Inc., Rahway, NJ, USA, 1983, p. 544, (entry 3697).

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US20040224947A1 (en) * 2000-07-26 2004-11-11 Moros Daniel A. Non-sedating barbiturate compounds as neuroprotective agents
US8158639B2 (en) 2000-07-26 2012-04-17 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US20060035915A1 (en) * 2000-07-26 2006-02-16 Taro Pharmaceutical Industries, Ltd. Non-sedating barbituric acid derivatives
US20060122208A1 (en) * 2000-07-26 2006-06-08 Daniella Gutman Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US20060205747A1 (en) * 2000-07-26 2006-09-14 Moros Daniel A Non-sedating barbiturate compounds as neuroprotective agents
US8076346B2 (en) 2000-07-26 2011-12-13 Taro Pharamaceutical Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US20100144769A1 (en) * 2000-07-26 2010-06-10 Taro Pharmaceutical Industries Limited Composition and method for improved bioavailability and enhanced brain delivery of 5 5-diphenyl barbituric acid
US7723346B2 (en) 2000-07-26 2010-05-25 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US20110144330A1 (en) * 2002-02-01 2011-06-16 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine Compounds and their Uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US20040029902A1 (en) * 2002-02-01 2004-02-12 Rajinder Singh 2,4-Pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US20070225321A1 (en) * 2002-02-01 2007-09-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7906644B2 (en) 2002-02-01 2011-03-15 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8314115B2 (en) 2002-12-11 2012-11-20 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives
US7776871B2 (en) 2002-12-11 2010-08-17 Taro Pharmaceutical Industries Ltd. Method of treating movement disorders using barbituric acid derivatives
US20070072886A1 (en) * 2002-12-11 2007-03-29 Daniel Moros Method of treating movement disorders using barbituric acid derivatives
US20080312438A1 (en) * 2003-07-30 2008-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20050234049A1 (en) * 2003-07-30 2005-10-20 Rajinder Singh Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20090124580A1 (en) * 2005-01-19 2009-05-14 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7563892B1 (en) 2005-01-19 2009-07-21 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4 pyrimidinediamine compounds and their uses
US20060234983A1 (en) * 2005-01-19 2006-10-19 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
WO2012058216A2 (en) 2010-10-27 2012-05-03 The Gillette Company Composition dispensing device comprising a non-foaming hydrating composition
WO2013025772A2 (en) 2011-08-16 2013-02-21 The Gillette Company Composition dispensing device comprising a moisturizing composition
WO2015066486A1 (en) 2013-11-01 2015-05-07 The Gillette Company Shave care composition for a liquid dispensing razor

Also Published As

Publication number Publication date
US20030018080A1 (en) 2003-01-23
DE69820895D1 (en) 2004-02-05
ATE257153T1 (en) 2004-01-15
CN1699349A (en) 2005-11-23
EP1027339B1 (en) 2004-01-02
CA2304970C (en) 2010-07-13
US6664262B2 (en) 2003-12-16
ATE299500T1 (en) 2005-07-15
EP1342718B1 (en) 2005-07-13
WO1999018084A1 (en) 1999-04-15
PT1342718E (en) 2005-11-30
DK1342718T3 (en) 2005-09-26
EP1027339A1 (en) 2000-08-16
CN1193019C (en) 2005-03-16
JP4061018B2 (en) 2008-03-12
US20040167358A1 (en) 2004-08-26
JP2001519334A (en) 2001-10-23
AU9597698A (en) 1999-04-27
DE69830860D1 (en) 2005-08-18
ES2214736T3 (en) 2004-09-16
IL135284A (en) 2005-11-20
AU758506B2 (en) 2003-03-20
EP1342718A1 (en) 2003-09-10
IL165080A0 (en) 2005-12-18
DE69830860T2 (en) 2006-04-27
US6906079B2 (en) 2005-06-14
PT1027339E (en) 2004-05-31
CN1273581A (en) 2000-11-15
DK1027339T3 (en) 2004-05-03
ES2243833T3 (en) 2005-12-01
US6093820A (en) 2000-07-25
JP2008101002A (en) 2008-05-01
CA2304970A1 (en) 1999-04-15
DE69820895T2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
USRE38934E1 (en) Method and reagents for N-alkylating ureides
US6566532B2 (en) Process for producing optically active hemiesters
EP0205879B1 (en) Process for the preparation of herbicidal 2-(4,4-disubstituted 5-oxo-2-imidazolin-2-yl)benzoic, nicotinic and quinoline-3-carboxylic acids, esters and salts
CZ297005B6 (en) Process for preparing sulfonamide-substituted imidazotriazinones
SK158094A3 (en) Method of production 1-(alkoxymethyl) pyrole compounds
US6307053B1 (en) Process for preparing imidacloprid
CA1271769A (en) 4-alkoxy-3-pyrrolin-2-on-1-yl acetic acid alkyl esters and their production
US3880871A (en) Isothiocyanophenyl substituted imidazoles
US5486617A (en) Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes
US4480130A (en) Preparation of ortho-(alkylthiomethyl) anilines by catalytic sulfilimine rearrangement
US4833141A (en) 4-[4-[[2-(halophenyl)-2-[1H-tr:azol(or diazol)-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine-1-carbimic acids having antimycotic activity
CA1274850A (en) .alpha.-CHLOROKETONE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF
JP3716435B2 (en) Process for producing 2-substituted-5-chloroimidazole-4-carbaldehyde
GB1561516A (en) 1-(azacylic aralkoxyphenyl) - 2 - or - 3-(bis -arylalkylamino alkanes process for their manufacture and pharmaceutical preparation containint them
US6964963B2 (en) Preparation of 4-amino-1-naphthol ethers
HK1000096B (en) Process for the preparation of herbicidal 2-(4,4-disubstituted 5-oxo-2-imidazolin-2-yl)benzoic, nicotinic and quinoline-3-carboxylic acids, esters and salts

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12